MONOPAR THERAPEUTICS INC (MNPR) — insider trading
Health Care · NASDAQ
MONOPAR THERAPEUTICS INC (MNPR) has 24 reported SEC Form 4 insider transactions in our data (latest 2026-06-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | Cittadine Andrew | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 5,254 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Cittadine Andrew | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 2,309 | $92.59 | $213.8K | Form 4 |
| 2026-06-30 | Cittadine Andrew | Officer (Chief Operating Officer) | Option exercise / conversion | 5,254 | — | — | Form 4 |
| 2026-06-30 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 12,873 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 4,084 | $92.59 | $378.1K | Form 4 |
| 2026-06-30 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 12,873 | — | — | Form 4 |
| 2026-06-30 | Vu Quan Anh | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 1,228 | $0.00 | $0 | Form 4 |
| 2026-06-30 | Vu Quan Anh | Officer (Chief Financial Officer) | Shares withheld for taxes / exercise cost | 507 | $92.59 | $46.9K | Form 4 |
| 2026-06-30 | Vu Quan Anh | Officer (Chief Financial Officer) | Option exercise / conversion | 1,228 | — | — | Form 4 |
| 2026-06-26 | Sweeny Nicole | Director | Grant / award / vesting (derivative) | 1,284 | $0.00 | $0 | Form 4 |
| 2026-03-31 | Cittadine Andrew | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 3,514 | $0.00 | $0 | Form 4 |
| 2026-03-31 | Cittadine Andrew | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 1,571 | $54.79 | $86.1K | Form 4 |
| 2026-03-31 | Cittadine Andrew | Officer (Chief Operating Officer) | Option exercise / conversion | 3,514 | — | — | Form 4 |
| 2026-03-31 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 6,732 | $0.00 | $0 | Form 4 |
| 2026-03-31 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 1,972 | $54.79 | $108.0K | Form 4 |
| 2026-03-31 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 6,732 | — | — | Form 4 |
| 2026-03-02 | Rodriguez Susan | Officer (CCSO) | Grant / award / vesting (derivative) | 48,728 | $0.00 | $0 | Form 4 |
| 2025-12-31 | Cittadine Andrew | Officer (Chief Operating Officer) | Option exercise / conversion (derivative) | 4,326 | $0.00 | $0 | Form 4 |
| 2025-12-31 | Cittadine Andrew | Officer (Chief Operating Officer) | Shares withheld for taxes / exercise cost | 1,889 | $65.30 | $123.4K | Form 4 |
| 2025-12-31 | Cittadine Andrew | Officer (Chief Operating Officer) | Option exercise / conversion | 4,326 | — | — | Form 4 |
| 2025-12-31 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 8,724 | $0.00 | $0 | Form 4 |
| 2025-12-31 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Shares withheld for taxes / exercise cost | 2,558 | $65.30 | $167.0K | Form 4 |
| 2025-12-31 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 8,724 | — | — | Form 4 |
| 2025-01-28 | Robinson Chandler | Director, Officer (Chief Executive Officer) | Other acquisition or disposition | 62,815 | $0.00 | $0 | Form 4 |
Ask the chat about MNPR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MONOPAR THERAPEUTICS INC (MNPR).
Last updated 2026-06-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.